RNA‐based methods, such as microRNA, siRNA, and long non‐coding RNAs, have shown utility in reducing GPC3 expression and inhibiting HCC progression.[34] However, these methods are hampered by persistent residual gene expression and the necessity for continuous administration of prodrugs due to their transient inhibitory effects. Here, GPC3 is linked to hepatocellular carcinoma.